Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Anavex Life Sciences Corp.

NASDAQ: AVXL · Life Sciences · 5 alerts · CIK 1314052

Share price
$0.8176Close, Nov 16
Market cap
$75.8M
Shares outstanding
92.7MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Anavex Life Sciences Corp. filings on SEC EDGAR ↗

4:16 PM ET 8-K
Business Update

Anavex Life Sciences Business Update

Anavex Life Sciences announced the completion of clinical conduct for two pharmacology studies (ADME and DDI) for blarcamesine (ANAVEX 2-73) in healthy volunteers. The company also reported FDA clearance of its IND application for Fragile X syndrome and an upcoming November meeting with the FDA regarding its Phase 3 Rett syndrome study.

4:18 PM ET 8-K
Business Update

Anavex Life Sciences Business Update

Anavex Life Sciences received FDA clearance for its Investigational New Drug (IND) application for blarcamesine (ANAVEX 2-73) to treat Fragile X syndrome. This allows the company to proceed with a Phase 2a clinical study in approximately 60 adult males, marking a key milestone as the company now has open INDs in Alzheimer’s, Rett syndrome, and Fragile X.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.